Neuroprotection in Huntington's disease

被引：0

作者：

Bonelli, RM ^{[1
]}

Hödl, AK ^{[1
]}

Kapfhammer, HP ^{[1
]}

机构：

[1] Graz Med Univ, Univ Clin Psychiat, A-8036 Graz, Austria

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2005年 / 2卷 / 02期

关键词：

D O I：

10.2174/1570180053175133

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Minocycline, the 7-dimethylamino- 6-dimethyl-desoxytetracycline hydrochloride, is a caspase-1 inhibitor and may serve as anti-apoptotic agent, thereby acting neuroprotective. It directly inhibits both caspase-independent and -dependent mitochondrial cell death pathways, and decreases inducible nitric oxide synthetase activity. Minocycline delays disease progression in the transgenic mouse model of Huntington's disease (HD), extending survival by 14%. HD is a late onset relentlessly progressive, neurodegenerative disorder with currently no cures or even effective therapies, death occurring 15 years after onset. In this review, recent clinical and preclinical data on minocycline in HD and neuroprotective alternatives discussed.

引用

页码：143 / 147

页数：5

共 50 条

[31] ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease [J].

Maher, Pamela ;

Dargusch, Richard ;

Bodai, Laszlo ;

Gerard, Paul E. ;

Purcell, Judith M. ;

Marsh, J. Lawrence .

HUMAN MOLECULAR GENETICS, 2011, 20 (02) :261-270

[32] Neuroprotection by ADAM10 inhibition requires TrkB signaling in the Huntington's disease hippocampus [J].

Scolz, Andrea ;

Vezzoli, Elena ;

Villa, Michela ;

Talpo, Francesca ;

Cazzola, Jessica ;

Raffin, Francesca ;

Cordiglieri, Chiara ;

Falqui, Andrea ;

Pepe, Giuseppe ;

Maglione, Vittorio ;

Besusso, Dario ;

Biella, Gerardo ;

Zuccato, Chiara .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2024, 81 (01)

[33] Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF [J].

McBride, JL ;

During, MJ ;

Wuu, J ;

Chen, EY ;

Leurgans, SE ;

Kordower, JH .

EXPERIMENTAL NEUROLOGY, 2003, 181 (02) :213-223

[34] Huntington's disease of early onset or juvenile Huntington's disease [J].

Gordon, N .

HOSPITAL MEDICINE, 2003, 64 (10) :576-580

[35] Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease [J].

Loi, Samantha M. ;

Walterfang, Mark ;

Velakoulis, Dennis ;

Looi, Jeffrey C. L. .

AUSTRALASIAN PSYCHIATRY, 2018, 26 (04) :376-380

[36] Huntington's Disease [J].

Kowalski, Peter C. ;

Belcher, David C. ;

Keltner, Norman L. ;

Dowben, Jonathan S. .

PERSPECTIVES IN PSYCHIATRIC CARE, 2015, 51 (03) :157-161

[37] Huntington's disease [J].

Heilbrunn, J .

NEW REPUBLIC, 1997, 217 (23) :4-+

[38] Reply to Valenza and Cattaneo: SIRT2-mediated neuroprotection and cholesterol dyshomeostasis in Huntington's disease [J].

Luthi-Carter, Ruth ;

Kazantsev, Aleksey G. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (37) :16000-16000

[39] Huntington's disease [J].

不详 .

NATURE, 2018, 557 (7707) :S35-S35

[40] Huntington's disease [J].

Walker, Francis O. .

LANCET, 2007, 369 (9557) :218-228

← 1 2 3 4 5 →